Nebenwirkungen · M-M-RVaxPro
M-M-RvaxPro powder and solvent for suspension for injection M-M-RvaxPro powder and solvent for suspension for injection in pre-filled syringe Measles, mumps and rubella vaccine (live) · Abschnitt 4.8 · PDF-Seite 7
HOS-114029 · Präparat HOS-094015
Additionally, other adverse reactions reported with post-marketing use of M-M-RvaxPro and/or in clinical studies and post-marketing use of previous formulations of monovalent and of the combined measles, mumps and rubella vaccines manufactured by MSD without regard to causality or frequency are available and are summarised in section b. The frequency of these adverse events is qualified as "not known" when it cannot be estimated based on the available data. These data were reported based on more than 400 million doses distributed worldwide.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-30T16:34:00Z · SHA-256 1f84b715b09e24aaf9cb7a48ff222d83aa13b8cc05114993c41c6a61cefc89b7 · Passage ae855e13857fa701de90a037e5074dd0defb7d76213513efd3b355f50443dace · Zeichen 1014–1560 im Abschnitt